Crinetics Pharmaceuticals Inc
Închisă
SectorSănătate
84.95 0.13
Rezumat
Modificarea prețului
24h
Minim
84.95
Maxim
84.95
Venit | 7M -121M |
|---|---|
Vânzări | 14M 25M |
EPS | -1.14 |
Marjă de profit | -481.149 |
Angajați | 594 |
EBITDA | -4.7M -131M |
Recomandări | Neutru |
|---|---|
Prognoză pe 12 luni | +0.72% upside |
Capitalizare de piață | 148M 9B |
|---|---|
Deschiderea anterioară | 84.82 |
Închiderea anterioară | 84.95 |
Crinetics Pharmaceuticals Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Crinetics Pharmaceuticals Inc Așteptări
Obiectiv de preț
By TipRanks
0.72% sus
Prognoză pe 12 luni
Medie 85.56 USD 0.72%
Maxim 95 USD
Minim 80 USD
În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.
Date financiare
$
Despre Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
